According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
A number of other equities research analysts have also issued reports on STML. HC Wainwright cut their price target on shares of Stemline Therapeutics from $35.00 to $20.00 and set a buy rating on the stock in a report on Tuesday. Alliance Global Partners started coverage on shares of Stemline Therapeutics in a report on Monday, November 25th. They issued a buy rating and a $21.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Stemline Therapeutics in a report on Tuesday, December 24th. They issued an overweight rating and a $18.00 price target on the stock. Wedbush cut their price target on shares of Stemline Therapeutics from $17.00 to $14.00 and set an outperform rating on the stock in a report on Thursday, January 16th. Finally, BidaskClub lowered shares of Stemline Therapeutics from a buy rating to a hold rating in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $20.00.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. The firm had revenue of $13.33 million during the quarter, compared to the consensus estimate of $13.40 million. As a group, equities research analysts anticipate that Stemline Therapeutics will post -1.82 EPS for the current year.
In other news, COO Kenneth Hoberman sold 13,228 shares of Stemline Therapeutics stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $10.37, for a total transaction of $137,174.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 13.10% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in shares of Stemline Therapeutics during the 2nd quarter valued at about $52,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Stemline Therapeutics by 51.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,466 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Stemline Therapeutics by 364.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 7,115 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 5,583 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Stemline Therapeutics by 18.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 11,004 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 1,715 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new stake in shares of Stemline Therapeutics during the 2nd quarter valued at about $175,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Story: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.